Personalized Medicine for High Alert Drugs in Respiratory Diseases

Background: Personalized medicine has significant potential for enhancing high-alert respiratory medication treatment, particularly emphasizing pharmacogenomics. Understanding the impact of genetic variations on drug responses can lead to improved patient care and minimized adverse reactions. This study reviews the current status and challenges of personalized medicine in high-alert respiratory drugs, exploring its potential to modify patient care and treatment outcomes. The main body of the abstract: This study aims to explore the application of personalized medicine in high-alert respiratory drugs by considering genetic factors and individual variations. The objective is to enhance patient safety and treatment efficacy while reducing the burden of respiratory diseases. The study discusses the genetic determinants of drug response in bronchodilator therapy (Albuterol, Salmeterol, and Formoterol), corticosteroid response (Fluticasone, Budesonide, and Prednisone), and anaesthesia (propofol) in respiratory problems. It highlights the role of pharmacogenomics in optimizing drug effectiveness and reducing adverse reactions. Additionally, the study emphasizes the significance of genetic variability and genotype-based therapies. Conclusion: Personalized medicine, especially pharmacogenomics, can change high-alert respiratory drug treatment by tailoring therapies based on individual genetic profiles. Despite challenges, implementing personalized medicine can improve patient care and treatment outcomes. Further research is essential to overcome barriers and integrate pharmacogenomics into routine healthcare for personalized respiratory drug therapy.